Grass pollen vaccine

Unassigned

New Medicines

Seasonal allergic rhinitis

Information

Vaccine
Allergy Therapeutics
Allergy Therapeutics

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Grass MATA MPL contains three distinct components: allergens combined with a micro-crystalline tyrosine (MCT) dept to enhanced immune exposure and improved tolerability and a toll-like 4 receptor (TLR4) agonist; monophosphoryl lipid A (MPL®).
Grass allergy, the most common cause of hay fever, is extremely prevalent. In Europe and the United States approximately 17 – 27% of the population are sensitized to pollen from different grass species [1].
Seasonal allergic rhinitis
Subcutaneous injection